4D Molecular Therapeutics completed enrollment for 4FRONT-1, a phase 3 trial of 4D-150, an investigational therapy designed to deliver sustained anti-VEGF treatment via single intravitreal injection for retinal disease. Topline efficacy data are anticipated in the first half of 2027, with a second pivotal trial completing enrollment by mid-2026.
Key Points
- 4FRONT-1 enrolled 523 patients; randomization complete March 2026
- Single injection therapy aims for multi-year anti-VEGF duration
- Phase 3 data expected H1 2027; second trial data H2 2027
Longevity Analysis
Sustained anti-VEGF delivery addresses a critical mechanism in age-related retinal degeneration, where vascular overgrowth and leakage accelerate vision loss. Moving from frequent injections to single-dose durability reduces treatment burden and improves adherence—factors that determine whether patients can maintain visual function over decades. The shift from repeated procedures to sustained pharmacological support directly impacts how well the vascular and regenerative systems preserve retinal tissue, a cornerstone of healthy aging vision.
Original published by LT Wire.